These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35848622)

  • 1. Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels.
    Camara-Lemarroy C; Metz L; Kuhle J; Leppert D; Willemse E; Li DK; Traboulsee A; Greenfield J; Cerchiaro G; Silva C; Yong VW
    Mult Scler; 2022 Nov; 28(13):2081-2089. PubMed ID: 35848622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis.
    Camara-Lemarroy C; Silva C; Gohill J; Yong VW; Koch M
    Eur J Neurol; 2023 Jan; 30(1):187-194. PubMed ID: 36214614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis.
    Koerbel K; Maiworm M; Schaller-Paule M; Schäfer JH; Jakob J; Friedauer L; Steffen F; Bittner S; Foerch C; Yalachkov Y
    Mult Scler Relat Disord; 2024 Jul; 87():105644. PubMed ID: 38701697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis.
    Pauwels A; Van Schependom J; Devolder L; Van Remoortel A; Nagels G; Bjerke M; D'hooghe MB
    Mult Scler; 2022 Oct; 28(11):1685-1696. PubMed ID: 36059263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of serum neurofilaments in patients with clinically isolated syndromes.
    Dalla Costa G; Martinelli V; Sangalli F; Moiola L; Colombo B; Radaelli M; Leocani L; Furlan R; Comi G
    Neurology; 2019 Feb; 92(7):e733-e741. PubMed ID: 30635483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofilament light chain as a biomarker in neuromyelitis optica spectrum disorder: a comprehensive review and integrated analysis with glial fibrillary acidic protein.
    Kim S; Lee JJ; Park JS; Kang M; Seok HY
    Neurol Sci; 2024 Mar; 45(3):1255-1261. PubMed ID: 38141119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NfL and GFAP in serum are associated with microstructural brain damage in progressive multiple sclerosis.
    Ammitzbøll C; Dyrby TB; Börnsen L; Schreiber K; Ratzer R; Romme Christensen J; Iversen P; Magyari M; Lundell H; Jensen PEH; Sørensen PS; Siebner HR; Sellebjerg F
    Mult Scler Relat Disord; 2023 Sep; 77():104854. PubMed ID: 37418931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease.
    Mao S; Teng X; Li Z; Zu J; Zhang T; Xu C; Cui G
    Brain Res; 2023 Apr; 1805():148271. PubMed ID: 36754139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum glial fibrillary acidic protein and neurofilament light chain in treatment-naïve patients with unipolar depression.
    Hviid CVB; Benros ME; Krogh J; Nordentoft M; Christensen SH
    J Affect Disord; 2023 Oct; 338():341-348. PubMed ID: 37336248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between serum neurofilament light chain and glial fibrillary acidic protein with the REM sleep behavior disorder subtype of Parkinson's disease.
    Teng X; Mao S; Wu H; Shao Q; Zu J; Zhang W; Zhou S; Zhang T; Zhu J; Cui G; Xu C
    J Neurochem; 2023 Apr; 165(2):268-276. PubMed ID: 36776136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurofilament Light Chain and Glial Fibrillary Acidic Protein as early prognostic biomarkers after out-of-hospital cardiac arrest.
    Klitholm M; Jeppesen AN; Christensen S; Parkner T; Tybirk L; Kirkegaard H; Sandfeld-Paulsen B; Grejs AM
    Resuscitation; 2023 Dec; 193():109983. PubMed ID: 37778613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma glial fibrillary acidic protein levels correlate with paramagnetic rim lesions in people with radiologically isolated syndrome.
    Schneider R; Brand-Arzamendi K; Reynold Lim T; Lee LE; Guenette M; Suthiphosuwan S; Bharatha A; Oh J
    Mult Scler; 2024 Feb; 30(2):156-165. PubMed ID: 38145319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofilament light, glial fibrillary acidic protein, and tau in a regional epilepsy cohort: High plasma levels are rare but related to seizures.
    Akel S; Asztely F; Banote RK; Axelsson M; Zetterberg H; Zelano J
    Epilepsia; 2023 Oct; 64(10):2690-2700. PubMed ID: 37469165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum neurofilament light chain is more strongly associated with T2 lesion volume than with number of T2 lesions in patients with multiple sclerosis.
    Wenger KJ; Hoelter MC; Yalachkov Y; Hendrik Schäfer J; Özkan D; Steffen F; Bittner S; Hattingen E; Foerch C; Schaller-Paule MA
    Eur J Radiol; 2023 Sep; 166():111019. PubMed ID: 37549559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofilament light chain level is a weak risk factor for the development of MS.
    Arrambide G; Espejo C; Eixarch H; Villar LM; Alvarez-Cermeño JC; Picón C; Kuhle J; Disanto G; Kappos L; Sastre-Garriga J; Pareto D; Simon E; Comabella M; Río J; Nos C; Tur C; Castilló J; Vidal-Jordana A; Galán I; Arévalo MJ; Auger C; Rovira A; Montalban X; Tintore M
    Neurology; 2016 Sep; 87(11):1076-84. PubMed ID: 27521440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum neurofilament and glial fibrillary acidic protein in idiopathic and seropositive transverse myelitis.
    Lee HL; Seok JM; Chung YH; Min JH; Baek SH; Kim SM; Sohn E; Kim J; Kang SY; Hong YH; Shin HY; Cho JY; Oh J; Lee SS; Kim S; Kim SH; Kim HJ; Kim BJ; Kim BJ
    Mult Scler Relat Disord; 2023 Nov; 79():104957. PubMed ID: 37688927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
    Arroyo Pereiro P; Muñoz-Vendrell A; León Moreno I; Bau L; Matas E; Romero-Pinel L; Martínez Yélamos A; Martínez Yélamos S; Andrés-Benito P
    J Neurol; 2024 Apr; 271(4):1599-1609. PubMed ID: 38085343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of aerobic exercise on Neurofilament light chain and glial Fibrillary acidic protein level in patients with relapsing remitting type multiple sclerosis.
    Ercan Z; Bilek F; Demir CF
    Mult Scler Relat Disord; 2021 Oct; 55():103219. PubMed ID: 34433118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis.
    Niiranen M; Kontkanen A; Jääskeläinen O; Tertsunen HM; Selander T; Hartikainen P; Huber N; Solje E; Haapasalo A; Kokkola T; Lohioja T; Herukka SK; Simula S; Remes AM
    Mult Scler Relat Disord; 2021 Nov; 56():103280. PubMed ID: 34627002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum β-synuclein, neurofilament light chain and glial fibrillary acidic protein as prognostic biomarkers in moderate-to-severe acute ischemic stroke.
    Barba L; Vollmuth C; Abu-Rumeileh S; Halbgebauer S; Oeckl P; Steinacker P; Kollikowski AM; Schultz C; Wolf J; Pham M; Schuhmann MK; Heuschmann PU; Haeusler KG; Stoll G; Neugebauer H; Otto M
    Sci Rep; 2023 Nov; 13(1):20941. PubMed ID: 38017278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.